IL-38, a potential therapeutic agent for lupus, inhibits lupus progression

ConclusionIL-38 regulates SLE pathogenesis. Furthermore, targeting IL-38 is critical in the treatment of SLE.
Source: Inflammation Research - Category: Research Source Type: research